Reactivating Circadian Rhythms as a Therapeutic Strategy: Insights from Basic Research
Biological and Pharmaceutical Bulletin · 01.08.2025 · 48 (8) · 1165-1171
DOI: 10.1248/bpb.b25-00330 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biological and Pharmaceutical Bulletin, erschienen am 01.08.2025. Verfasst von Masao Doi. Beteiligte Einrichtung: Department of Systems Biology, Graduate School of Pharmaceutical Sciences, Kyoto University. Hauptthemen laut MEDLINE: Circadian Rhythm. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben.
Abstract (Originalsprache)
One of the most significant conceptual changes brought about by the discovery of clock genes and development of circadian-clock mutant mice is the recognition that impaired circadian rhythmicity extends its impact far beyond sleep, driving pathogenesis of a wide variety of disorders such as cancer, obesity, and hypertension. However, despite this growing clinical evidence, chronobiology still lacks a coherent answer to the converse question: can restoration of circadian rhythms ameliorate-or even reverse-such diseases? In this review, three complementary pharmacological strategies-each still in preclinical development-are explored. First, direct modulation of the transcription-translation feedback loop (TTFL)-the core gene-regulatory circuit that generates 24-h rhythms in almost all nucleated cells-is reviewed as an approach to manipulation of cellular circadian biology. Second, the suprachiasmatic nucleus (SCN)-enriched G-protein-coupled receptor Gpr176 is highlighted as a central-clock target, given its ligand-independent, Gz-mediated control of cAMP signaling and demonstrated ability to reset the master pacemaker. Third, the concept of rhythmic enhancement of output function is introduced and exemplified by describing re-activation of circadian oxidized form of nicotinamide adenine dinucleotide (NAD+)-dependent 3β-hydroxy-steroid dehydrogenase (3β-HSD) activity in the meibomian gland-using nicotinamide mononucleotide (NMN)-to restore peripheral clock-driven steroidogenesis in this tissue, which leads to amelioration of meibomian gland dysfunction, a leading cause of dry eye disease. This review aims to highlight the molecular logic of each strategy; both mechanistic insights and safety/efficacy considerations are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Systems Biology, Graduate School of Pharmaceutical Sciences, Kyoto University.
Zitieren
APA
Doi, M. (2025). Reactivating Circadian Rhythms as a Therapeutic Strategy: Insights from Basic Research. Biological and Pharmaceutical Bulletin, 48(8), 1165-1171. https://doi.org/10.1248/bpb.b25-00330
Vancouver
Doi M. Reactivating Circadian Rhythms as a Therapeutic Strategy: Insights from Basic Research. Biological and Pharmaceutical Bulletin. 2025;48(8):1165-1171. doi:10.1248/bpb.b25-00330
BibTeX
@article{Doi2025,
author = {Doi, Masao},
title = {Reactivating Circadian Rhythms as a Therapeutic Strategy: Insights from Basic Research},
journal = {Biological and Pharmaceutical Bulletin},
year = {2025},
volume = {48},
number = {8},
pages = {1165--1171},
doi = {10.1248/bpb.b25-00330}
}
EUVIMED